FILTER
FILTERED INTERVIEW RESULTS
Roger Erickson
CEO AND FOUNDER, INTERBIOME
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."
Jan Kengelbach
CEO, AENOVA GROUP
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."
Donna LaVoie
PRESIDENT AND CEO, LAVOIEHEALTHSCIENCE
"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."
Daniel Prince
CEO, PRINCE STERILIZATION SERVICES
"The expansion will allow Prince to more than double its headcount, increase manufacturing capacity, and offer additional ready-to-use products and sterilization services to the market."
Tom Sellig
CEO, ADARE PHARMA SOLUTIONS
"For every challenge, we have a set of tools we can leverage to create optimized solutions beyond taste masking."
Louis Kassa
PRESIDENT AND CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"I hope to continue seeing companies coming from across the country contributing to the significant growth of the greater Philadelphia area in life sciences."
Denis Dufrane
CO-FOUNDER AND CEO, NOVADIP
"I believe 2023 and 2024 will be key for Novadip. We have already closed two trials in the autologous program. We are now in Phase 1/2 trials for CPT in young patients, both in the US and in Europe."
Jeff Butler
PRESIDENT, AMPAC FINE CHEMICALS
"AFC’s core technology differentiators include energetic chemistry, high potency manufacturing, and extensive chromatographic separation capabilities."
Tyrone Brewer
PRESIDENT, US ONCOLOGY, JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
"I am excited about Janssen’s aspirational vision to eliminate cancer. With targeted therapies and immunotherapies, cancer treatment can be more effective and less toxic, enabling individuals to manage their disease while also maintaining their quality of life."
Joe Panetta
PRESIDENT AND CEO, BIOCOM CALIFORNIA
"The lifecycle of new product introduction into the market will now be shorter, as companies have fewer years to recover revenue as a result of the IRA."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
